WO2012011675A2 - Additif alimentaire comprenant un minéral silicaté fermenté spécialement pour remplacer les antibiotiques, pour réguler la fonction immunitaire et promouvoir la croissance chez les animaux, et procédé de production de celui-ci - Google Patents

Additif alimentaire comprenant un minéral silicaté fermenté spécialement pour remplacer les antibiotiques, pour réguler la fonction immunitaire et promouvoir la croissance chez les animaux, et procédé de production de celui-ci Download PDF

Info

Publication number
WO2012011675A2
WO2012011675A2 PCT/KR2011/004618 KR2011004618W WO2012011675A2 WO 2012011675 A2 WO2012011675 A2 WO 2012011675A2 KR 2011004618 W KR2011004618 W KR 2011004618W WO 2012011675 A2 WO2012011675 A2 WO 2012011675A2
Authority
WO
WIPO (PCT)
Prior art keywords
weight
silicate mineral
feed
present
feed additive
Prior art date
Application number
PCT/KR2011/004618
Other languages
English (en)
Korean (ko)
Other versions
WO2012011675A3 (fr
Inventor
이종두
우희종
Original Assignee
서울대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 서울대학교 산학협력단 filed Critical 서울대학교 산학협력단
Publication of WO2012011675A2 publication Critical patent/WO2012011675A2/fr
Publication of WO2012011675A3 publication Critical patent/WO2012011675A3/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/20—Inorganic substances, e.g. oligoelements
    • A23K20/28—Silicates, e.g. perlites, zeolites or bentonites

Definitions

  • the present invention relates to a feed additive comprising a silicate mineral, a method for producing the same and an animal feed comprising the feed additive.
  • the present invention has been made to solve the problems of the prior art as described above, the problem to be solved in the present invention is an additive for feed antibiotics, a method for producing a purified silicate mineral for promoting the growth of the animal and for the animal comprising the same It is to provide a feed.
  • the present invention provides a method for producing a feed additive comprising a refined silicate mineral, comprising the following steps:
  • step (b) pulverizing the raw silicate mineral obtained from step (a) to a diameter of 320mesh or less;
  • step (d) sterilizing and drying the resultant obtained in step (c);
  • step (e) removing impurities contained in the resultant obtained in step (d);
  • step (f) aging by mixing distilled water with the resultant obtained in step (e).
  • Removal of heavy metals and harmful components in step (c) is preferably using a magnet.
  • Sterilization of the step (d) is rotation sterilized for 1 to 3 hours at 320 ⁇ 400 °C, the drying is preferably natural drying.
  • the removal of impurities in the step (e) is a method of precipitation by adding distilled water.
  • the aging step (f) is preferably aged for 5 to 10 days at 1-2m in the ground.
  • Purified silicate mineral obtained above is SiO 2 50-60% by weight, Al 2 O 3 10-20% by weight, Fe 2 O 3 5-10% by weight, CaO 0.1-5% by weight, MgO 1-5% by weight, K it comprises a 2 O 1 ⁇ 5 wt%, Na 2 O 0.1 ⁇ 5 wt%, MnO 0.01 ⁇ 1% by weight, TiO 2 0.1 ⁇ 5 wt% of P 2 O 5 0.01 ⁇ 1% by weight is preferred.
  • the present invention provides an additive for feed prepared by the manufacturing method.
  • the present invention also provides an animal feed comprising the feed additive of the present invention.
  • the present invention preferably provides an animal feed comprising 20 to 50% by weight of the feed additive of the present invention and 50 to 80% by weight of the general feed.
  • the animal feed of the present invention has the effect of blocking the side effects caused by the growth of the subject and the use of antibiotics.
  • FIG. 1 is a test report showing the component content of the purified silicate mineral according to a preferred embodiment of the present invention.
  • the sample name "Autumic Blood Soil" on the test report indicates the purified silicate mineral of the present invention.
  • FIG. 2 is an antimicrobial test report of a purified silicate mineral according to a preferred embodiment of the present invention.
  • the sample name "Autumic Blood Soil" on the test report indicates the purified silicate mineral of the present invention.
  • FIG 3 is an emissivity / radiation energy test report of the purified silicate mineral according to a preferred embodiment of the present invention.
  • the sample name "Autumic Blood Soil" on the test report indicates the purified silicate mineral of the present invention.
  • Figure 4 is a photograph showing the silicate minerals collected according to a preferred embodiment of the present invention.
  • 5a and 5b is a view showing the results of the antimicrobial test of the silicate mineral in accordance with a preferred embodiment of the present invention.
  • 6A and 6B are graphs showing the results of emissivity and radiation energy of silicate minerals according to a preferred embodiment of the present invention.
  • Figure 7 is a photograph comparing the digestive organs of the individual feed fed the feed group containing the feed additive of the present invention and the feed additive of the present invention.
  • FIG. 8 is a graph showing the survival rate of colorectal cancer SNUC2A cell line of the purified silicate mineral of the present invention. "Yangmingseok” on the graph represents the refined silicate mineral of the present invention. Significant difference from germanium treated group (P ⁇ 0.05).
  • FIG. 9 is a graph showing the survival rate of gastric cancer SNU1 cell line of the purified silicate mineral of the present invention. "Yangmingseok” on the graph represents the refined silicate mineral of the present invention. Significant difference from germanium treated group (P ⁇ 0.05).
  • FIG. 10 is a photograph showing the dermal damage healing of the purified silicate mineral of the present invention. Wounds of each treatment group immediately after induction (Day 0) and end of experiment (Day 14).
  • 11A shows the state immediately after treatment of each treatment group after skin damage.
  • 11B shows the mean of each treatment group.
  • Figure 12 compares the weight change rate of experimental animals according to the treatment of the purified silicate mineral of the present invention.
  • FIG. 13 is a graph comparing the amount of TNF-a expression in experimental animals.
  • the silicate mineral, the feed additive of the present invention neutralizes and destroys harmful magnetic fields by generating and amplifying and dissipating 4 high natural heat and scalar wave at room temperature without adding electric devices or chemical components, and penetrates into the skin of an individual. Not only does it increase the rate of growth of individuals by promoting vascular metabolism, but also enhances immunity to pathogenic microorganisms, so that it may not be infected with various pathogenic diseases even if a separate antibiotic is not mixed with feed.
  • the harmful magnetic field refers to high magnetic fields such as water waves, electrons, current waves, etc., which cause harmful quantum energy by overlapping naturally occurring quantum fields to block quantum energy generation and cause diseases related to infection of pathogenic microorganisms with high permeability. .
  • Such silicate minerals include those obtained by processing raw silicate minerals at a depth of one to two meters underground in a particular area.
  • the specific area is a space in which healthy people, animals and plants grow and stop for a long time (a place where plants grow, a place where people and animals sleep), the surface temperature is higher than the surroundings, there is no moisture, and moss, It is desirable to have a clean, clean area where mold dies and dies out.
  • a material that emits heat and quantum energy in nature such as warm heat generated in a living thermophilic animal
  • a material that generates, amplifies, and radiates energy for activating a living organism by itself when a material that emits heat and quantum energy in nature, such as warm heat generated in a living thermophilic animal, is produced, a material that generates, amplifies, and radiates energy for activating a living organism by itself.
  • the silicate mineral of the present invention is collected in the sunny region as described above, and collects silicate minerals of hard nature and high cracking nature in unpolluted soil.
  • the collected silicate mineral is pulverized to 320mesh or less using a grinder, and the heavy metals and harmful components included in the ground silicate mineral are removed.
  • the pulverized silicate mineral is generally a silicate mineral crushed to a size of 320 mesh or less since the specific gravity to air is significantly lower than that of inorganic ores such as gold, silver, copper, iron, germanium, elvan, zeolite, bentonite, and jade.
  • the high magnetic force removes the heavy metals and harmful components contained in the silicate mineral by dispensing them to the refining drum through a conveyor equipped with strong magnets.
  • the silicate mineral administered to the tablet drum is sterilized for 1 to 3 hours with a heat of 320 ⁇ 400 °C, and performs a sterilization and drying step to naturally dry until the high temperature heat is cooled. Then, the impurities contained in the silicate mineral sterilized and dried are purified.
  • distilled water is administered in a ratio of 50: 50% by weight to a purification drum in which the silicate mineral is stored, and the mixed silicate mineral is mixed in distilled water by impeller mixing through an impeller installed in the purification drum.
  • the silicate mineral in the form of a slurry in which the mixing is completed causes delamination of the slurry for 30 to 45 minutes after the driving of the impeller is stopped, and due to the delamination, the silicate mineral is at the bottom of the purification drum and impurities The impurities are removed from the silicate mineral by allowing it to be separated into an upper layer of the silicate mineral.
  • silicate minerals made of fine particles having a diameter of 320mesh or less that can be commercialized in the extraction of silicate minerals are prepared, mixed with distilled water, stored in a sample storage container, and aged for 5 to 10 days in the ground. Let's do it.
  • the mixed silicate mineral and distilled water is mixed in a ratio of 50: 50% by weight and stored in a sealed sample storage container capable of storing up to 10L.
  • the silicate mineral stored in the sample storage container undergoes a aging process for a certain period of time, and the cold property of natural inorganic ore or soil disappears, and is changed into a cationic warm property, so that the energy of human energy and silicate mineral is changed to air at room temperature. It constantly reacts with cationic protons or photons to emit warm heat for humans to experience.
  • the silicate mineral of the present invention As such, the silicate mineral of the present invention, as shown in FIG.
  • the veins of natural inorganic ore that is not as pure stone in soil but as solid as non-colored bitumen stone but broken like soil
  • a vein made of the highest purity silicate mineral appears.
  • the veins made of this silicate mineral are short-wave, neutralize and extinguish harmful magnetic fields including permeable water-wave, and act as a catalyst to generate and amplify and continually radiate energy that activates animals. It contains 76 beneficial mineral minerals.
  • Such silicate mineral is 56.9% SiO 2 component, 17.4% Al 2 O 3 component, 9.49% Fe 2 O 3 component, 0.53% CaO component, 2.48% MgO component, K 2 O component, as shown in the analysis test report of FIG. 3.06%, 0.98% Na 2 O component, 0.087% MnO component, 0.76% TiO 2 component, 0.067% P 2 O 5 component and the balance O 2 .
  • Feed additives according to the method for producing a feed additive comprising a refined silicate mineral of the present invention as described above can be mixed with a general animal feed to produce an animal feed.
  • the animal feed of the present invention may include 20 to 50% by weight of the feed additive prepared by the manufacturing method and 50 to 80% by weight of the general feed.
  • the content of the additive is less than 20% by weight, the growth and replacement of antibiotics of the subjects desired in the present invention may be small, and when the content of the additive exceeds 50% by weight, the content of the relative general feed decreases, causing problems in normal growth. Can be.
  • the general feed is not particularly limited and may be for livestock and pet food.
  • the feed containing the feed additive of the present invention has an antibiotic effect, increases the disease resistance of the animal, and shows the weight gain of the animal.
  • the feed of the present invention can be safely fed as it does not exhibit any toxicity to animals. It is expected that the present invention will be able to replace conventional antibiotics because of these properties and effects.
  • the antimicrobial properties of the silicate minerals were tested.
  • the silicate mineral of the present invention was confirmed to have antimicrobial activity by Escherichia coli / S. Aureus.
  • Figure 5a is taken before and after the test of the E. coli in accordance with the above conditions, as a result of checking the state before the sample and the state after 24 hours, it was found that the E. coli population significantly decreased.
  • Figure 5b is taken before and after the test of Staphylococcus aureus according to the above conditions, as a result of confirming the state before the sample and 24 hours after the addition, as a result, the population of staphylococcus is completely reduced even with the naked eye I could see that.
  • the silicate mineral of the present invention was measured the emissivity of 0.920, it can be seen that the emission energy is 3.70 ⁇ 10 2 (W / m 2 ⁇ ⁇ m, 40 °C) is generated.
  • high-week-old Ovalbumin TCR-Transgenic mouse Central Laboratory Animal, Korea
  • the feed was fed a general feed for mouse
  • the experimental group was fed a feed prepared by mixing the feed additive of the present invention with a general feed and a ratio of 1: 3 (w / w), and the feed additive of the present invention.
  • Class was one group.
  • Feeding results were measured by measuring the body weight after 1 week, 2 weeks, and 3 weeks on day 0, and the digestive organs were compared by dissecting the mice at the end of the 3rd week of the experiment.
  • mice were dissected on the last day of the experiment (Day 21), and the digestive tracts of the feed group with the feed additive of the present invention and the feed additive of the present invention were compared. Was not observed (FIG. 7).
  • the feed additive of the present invention and the feed containing the same were able to confirm that the animal's body weight was significantly increased, and furthermore, the material of the present invention was not confirmed to be toxic to the animals.
  • the feed of the present invention may be fully utilized as a substitute for homeostasis.
  • the effect of the silicate mineral of the present invention on tumor cell activity was examined using a human tumor cell line, and at the same time, the following experiment was conducted to confirm the effect on the activation state of immune cells.
  • the plant of the sun is planted in 1: 1 (v / v) silicate mineral of the present invention (hereinafter referred to as Yangmyeongseok), germanium gel formulation as a stone powder control, and Yangmyeongseok provided by Yangmyeongseok Co., Ltd., which is related to quantum energy.
  • v silicate mineral of the present invention
  • Tumor cell lines to be used in the experiment were placed in a suitable culture solution (RPMI 1640, 10% FBS; GIBCO Inc., USA) and maintained at 37 ° C. 5% CO 2 .
  • Germanium gel was used as a control group of Yangmyeongseok gel and Seok-gun gel provided by Yangmyeong-seok.
  • the cells were incubated in a 96-well plate at a concentration determined according to the cell line.
  • the increase or decrease in the number of cancer cells at 24 hour intervals was confirmed by viability analysis along with cell number analysis. Survival was quantified by measuring the OD450 value using the CCK-8 assay kit (Dojindo Molecular Technologies, Inc., USA) to determine the untreated control group as 100% and then comparing it with the untreated control group.
  • SNUC2A cells were seeded at a rate of 100 ul / well in 96 well plates at a concentration of 3.3 ⁇ 104 cells / ml, and treated with Yangmyeongseok and germanium at a concentration of 0.25 mg / ml for each well.
  • SNU1 cells were dispensed at a rate of 100 ul / well in 96 well plates at a concentration of 1 ⁇ 105 cells / ml, and treated with Yangmyeong-seok and germanium at a concentration of 1.0 mg / ml for each well.
  • the survival rate was measured at a 24-hour interval after 3 days of tumor cell culture, and it was observed that the survival rate was significantly decreased in the Yangmyeongseok treatment group compared to the germanium treatment group at 48 hours and 72 hours. 8).
  • mice were isolated and housed one by one to prevent the mice from licking the wounds induced for the experiment and affecting the experimental results.
  • the area to induce wounds was depilated with an electric razor, and then a hair removal agent was applied to completely remove hairs.
  • mice were anesthetized with ether and punched to remove the epidermal and dermal layers and induced wounds to the myocardium.
  • skin damage experiments the skin was induced by anesthesia with ether, followed by removing the epidermal layer using sandpaper.
  • the treatment of Yangmyeongseok and Germanium gels provided by Yangmyeongseok Co., Ltd. was carried out so that the wound was sufficiently covered, and the commercial product was used according to the manufacturer's usage.
  • wound area was treated with phosphate buffered saline (PBS) 7 days and 14 days after wound induction, gel was removed with Kim wipes, and the wound area was measured with vernier calipers. This process was also applied to the untreated group and the commercial product treated group to eliminate intervariate variables.
  • PBS phosphate buffered saline
  • Wound healing scoring items are as follows.
  • the score for each item was 1-5 points according to the degree.
  • the score of a specific individual in the non-treated group was 3 points, and based on this, after scoring through comparison with the individual in each group, The scores of each item were summed up and scored for each group.
  • the weight change of the experimental animal subjects was also measured to see the effects of stress on the subjects.
  • Fig. 11A After using the sandpaper to cause epidermal damage, the sample was treated as shown in Fig. 11 (Fig. 11A). In the case of skin damage, the wound healing rate was slower than madecassol but faster than the germanium treated group. The mean value between the treatment groups showed a significant difference only in comparison with the untreated group and the germanium treated group (FIG. 11B).
  • Body weight was measured immediately after the wound induction (Day 0) and the last day of the experiment (Day 7), and the weight change was compared for each experimental group (FIG. 12). Body weight gain in Yangmyeongseok treatment group was significantly different from that of madecassol or germanium treatment group. In addition, the madecassol treatment group was significantly different from the untreated group.
  • 6-week-old DBA / 1J mouse Central Experimental Animal, Korea
  • the groups examined and compared in the experiment were set up as shown in Table 3.
  • a positive sample in the treatment of arthritis a commercial patch (trast; SK Chemicals, South Korea), which is widely distributed in the market, was used for the same purpose, and germanium gel was treated as a stone powder control group.
  • the Trast Patch a commercial product used as a positive sample for the experiment, is known to have anti-inflammatory, analgesic, and antipyretic functions with Piroxicam as its main ingredient. Piroxicam's specific mechanisms have been shown to inhibit prostaglandin synthesis, which causes inflammation and pain, to act on the hypothalamus's thermoregulatory center, to exhibit antipyretic effects, to reduce pain receptor sensitivity, and to have neutrophils. It is believed to have anti-inflammatory activity through the mechanism of inhibiting activity.
  • type collagen (Chondrex Inc., USA) was dissolved in 0.05 M acetic acid at 2 mg / ml, and complete Freund's adjuvant (CFA; Sigma Chemical Co., USA) was prepared, emulsified by mixing with each other while maintaining the type 2 collagen solution and CFA in a ratio of 1: 1 (v / v) cold, 100 ug of the mixture was injected into the tail.
  • CFA complete Freund's adjuvant
  • the second inoculation was used to mix the type 2 collagen with incomplete Freund's adjuvant (IFA; Sigma Chemical Co., USA) at a ratio of 1: 1 (v / v) to 100 ug for each individual. Tightly injected into the tail.
  • the degree of arthritis was observed once a week for up to 3 weeks and twice a week thereafter.
  • the degree of edema was assessed by calibrating the mice at 10, 20, and 30 days after application of the sample and taking a photograph.
  • the arthritis severity score of the four feet was assessed from 0 to 3 points, and the highest score was 12 points per individual.
  • the symptom among the total population was represented by the alleviated population and compared.
  • TNF-a ELISA kit (eBioscience Inc.) using monoclonal antibody was used to determine the concentration of TNF-a, an inflammatory cytokine. , USA) was used according to the manufacturer's data.
  • Splenocytes were extracted and dispensed 5 ⁇ 103 cells per well into a 96 well plate, and stabilized in RPMI 1640 (10% FBS, 1% antibiotics; GIBCO Inc., USA) at 37 ° C. and 5% CO 2 for 24 hours.
  • Type 2 collagen was treated at 0 ul / ml, 200 ul / ml. After 48 hours, the supernatant was collected and measured according to the manufacturer's instructions using a Total NO assay kit (R & D systems, USA).
  • the amount of TNF-a expression in the experimental animal subjects on the last day of treatment (Day 30) was compared for each experimental group (FIG. 13). After induction, the amount of TNF-a in the blood was decreased in Yangmyeongseok, Germanium, and Trast treated groups compared to the untreated group.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)

Abstract

L'invention est divulguée afin de pallier les limitations de la technique antérieure comme décrit ci-dessus et son objectif est de fournir une méthode de production d'un minéral silicaté purifié en tant qu'additif alimentaire produisant de l'énergie quantique, et un aliment pour animaux comprenant ledit additif. Lorsque l'aliment pour animaux de l'invention est utilisé, les effets secondaires provenant de l'utilisation de promoteurs de croissance et d'antibiotiques chez les individus sont supprimés.
PCT/KR2011/004618 2010-07-23 2011-06-24 Additif alimentaire comprenant un minéral silicaté fermenté spécialement pour remplacer les antibiotiques, pour réguler la fonction immunitaire et promouvoir la croissance chez les animaux, et procédé de production de celui-ci WO2012011675A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100071548A KR101197600B1 (ko) 2010-07-23 2010-07-23 특수 발효된 규산염 광물을 포함하는, 동물의 면역기능을 조절하고 성장을 촉진시키는 항생제 대체용 사료첨가제
KR10-2010-0071548 2010-07-23

Publications (2)

Publication Number Publication Date
WO2012011675A2 true WO2012011675A2 (fr) 2012-01-26
WO2012011675A3 WO2012011675A3 (fr) 2012-05-03

Family

ID=45497253

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/004618 WO2012011675A2 (fr) 2010-07-23 2011-06-24 Additif alimentaire comprenant un minéral silicaté fermenté spécialement pour remplacer les antibiotiques, pour réguler la fonction immunitaire et promouvoir la croissance chez les animaux, et procédé de production de celui-ci

Country Status (2)

Country Link
KR (1) KR101197600B1 (fr)
WO (1) WO2012011675A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101684457B1 (ko) * 2015-11-20 2016-12-08 김익헌 감을 포함하는 가축 사료 첨가제
KR101684458B1 (ko) * 2015-11-20 2016-12-08 김익헌 감을 먹여 콜레스테롤 함량이 낮은 육류 제품을 생산하는 방법
KR102564828B1 (ko) 2022-11-16 2023-08-08 김태윤 반려견의 장 건강 유지와 분변 냄새 감소용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000064152A (ko) * 2000-08-24 2000-11-06 이동남 견운 모질 도석광물의 실수율 및 품질향상 습식정제법과공정
JP2001299237A (ja) * 2000-04-20 2001-10-30 Kunimine Industries Co Ltd ミネラルイオン配合動物用飼料添加剤及びその製造方法
KR100554214B1 (ko) * 2005-07-20 2006-02-24 노영빈 허브초탄을 함유하는 사료첨가제 조성물 및 이를 사용하여사육된 동물성 식품
KR20090005930A (ko) * 2007-07-09 2009-01-14 서칠환 게르마늄을 함유한 저 콜레스테롤 축산육의 제조방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001299237A (ja) * 2000-04-20 2001-10-30 Kunimine Industries Co Ltd ミネラルイオン配合動物用飼料添加剤及びその製造方法
KR20000064152A (ko) * 2000-08-24 2000-11-06 이동남 견운 모질 도석광물의 실수율 및 품질향상 습식정제법과공정
KR100554214B1 (ko) * 2005-07-20 2006-02-24 노영빈 허브초탄을 함유하는 사료첨가제 조성물 및 이를 사용하여사육된 동물성 식품
KR20090005930A (ko) * 2007-07-09 2009-01-14 서칠환 게르마늄을 함유한 저 콜레스테롤 축산육의 제조방법

Also Published As

Publication number Publication date
KR101197600B1 (ko) 2012-11-09
KR20120010033A (ko) 2012-02-02
WO2012011675A3 (fr) 2012-05-03

Similar Documents

Publication Publication Date Title
Prateeksha et al. Scaffold of selenium nanovectors and honey phytochemicals for inhibition of Pseudomonas aeruginosa quorum sensing and biofilm formation
Jarald et al. Antioxidant and antimicrobial activities of cow urine
Abu-Seida Effect of propolis on experimental cutaneous wound healing in dogs
US20160317486A1 (en) Method for wound healing
KR101346306B1 (ko) 광물성 소마티드 추출방법 및 이를 이용한 다기능 첨단 소재 제조방법
WO2012011675A2 (fr) Additif alimentaire comprenant un minéral silicaté fermenté spécialement pour remplacer les antibiotiques, pour réguler la fonction immunitaire et promouvoir la croissance chez les animaux, et procédé de production de celui-ci
Adiele et al. Wound healing effect of methanolic leaf extract of Napoleona vogelii (Family: Lecythidaceae) in rats
ASHKANI et al. Enhancement of fibroblast proliferation, vascularization and collagen synthesis in the healing process of third-degree burn wounds by topical arnebia euchroma, a herbal medicine
JP2013060455A (ja) ハチ毒を有効成分とする組成物
Marasini et al. Analgesic activity of bark and leaves of Ficus religiosa L. from Nepal
KR20070054104A (ko) 피부염 발병 억제, 피부 창상의 치유 촉진효과를 가지는미생물 배양물 및 그것들을 이용한 제품
KR20080011847A (ko) 천연 항균제 및 그 제조 방법
Bakerspigel et al. The isolation of Phoma eupyrena from a human lesion
Hemmati et al. Wound healing effects of persian Oak (Quercus brantii) ointment in rats
WO2024071736A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies allergiques, contenant des cellules mortes de streptococcus pyogenes ou une protéine spea
KR101075006B1 (ko) 아토피 피부염 예방 및 치료용 조성물
MJ et al. Study of the Efficacy of Aloe Vera Extracts in Treatment of Non-Infected Wounds Induced by Sulferric Acid and Infected Wounds with Staphylococcus aureus.
KR20210030120A (ko) 항균 또는 항진균 조성물 및 이의 제조방법
WO2011155663A1 (fr) Procédé de construction respectueux de l'environnement à base de silice pour économiser des coûts de construction et de chauffage, réduire la période de construction, éliminer le poison de ciment et le syndrome du bâtiment malsain, et réduire la hauteur entre étages de bâtiments de grandes hauteurs
Salhi et al. Evaluation of the wound healing potential of Cynara humilis extracts in the treatment of skin burns
ÇELİK et al. Ranunculaceae Dermatitis due to Ranunculus Arvensis: Case Series, Literature Review of Reported Cases from Turkey
Eyarefe Healing potentials of Nigerian bee propolis on meticillin-resistant Staphylococcus aureus infected skin wound of wistar rats
KR100602924B1 (ko) 대추나무주홍하늘소 유충의 똥을 유효성분으로 하는 피부외용약
WO2004089430A1 (fr) Nouveau produit d'amelioration de cicatrisation de la peau
KR20210073697A (ko) 황색 클로렐라 추출물을 포함하는 화장료 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11809802

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11809802

Country of ref document: EP

Kind code of ref document: A2